• bacteria

    70% of hospital infections in the US are resistant to at least one antibiotic.

    —US Food and Drug Administration (FDA)

  • MRSA bacteria

    2 million antibiotic resistant infections annually in the US.

    —Centers for Disease Control and Prevention (CDC)

  • bacteria

    23,000 deaths in the US attributed to antibiotic resistant bacteria.

    —Centers for Disease Control and Prevention (CDC)

  • E. coli bacteria

    25,000 deaths in the European Union attributed to antibiotic resistant bacteria.

    —European Centre for Disease Control and Prevention (ECDC)

  • staph bacteria

    $21–34 billion in US healthcare costs due to antibiotic resistant bacteria.

    —Infectious Disease Society of America (IDSA)

VenatoRx receives Wellcome Trust funding

Supports research and development for novel treatments against
multi-drug resistant bacteria.

more

Antibiotic-resistant infections are a growing problem throughout the world. New strains are evolving and due to globalization, these antibiotic-resistant bacteria are spreading quickly throughout the world.  Unfortunately, antibiotic development has not kept pace and few novel products are being developed. Organizations throughout the world, such as the US Centers for Disease Control and Prevention (CDC), the European Centre for Disease Control and Prevention, and the Infectious Disease Society of America (IDSA), have issued a ‘call to arms’ to address this growing crisis.

At VenatoRx, we are dedicated to the discovery and development of the next generation of antibiotics. We focus on immediate and emerging threats, including both serious hospital and community infections, as well as potential biological warfare pathogens.